share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

SEC announcement ·  Jun 18 05:50
Summary by Futu AI
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock on June 13 and June 14, 2024. Secora acquired a total of 78,750 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 30,000 shares in the open market, with sale prices ranging from $9.2721 to $9.3199 per share, resulting in a total market value of $278,880 for the disposed shares. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amount to 1,267,843 shares of Class A Common Stock.
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock on June 13 and June 14, 2024. Secora acquired a total of 78,750 shares through the exercise of derivative securities at a price of $2.22 per share. Concurrently, he sold 30,000 shares in the open market, with sale prices ranging from $9.2721 to $9.3199 per share, resulting in a total market value of $278,880 for the disposed shares. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals amount to 1,267,843 shares of Class A Common Stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.